Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NAMS NewAmsterdam Pharma	$25.17 -2.3%	$21.20	$14.06 ▼ $27.29	$2.89B	-0.02	839,035 shs	606,186 shs
OGN Organon & Co.	$9.39 +0.3%	$9.75	$8.01 ▼ $23.10	$2.43B	0.6	4.75 million shs	3.58 million shs
PHAR Pharming Group	$11.38 +1.2%	$10.88	$6.73 ▼ $17.08	$770.79M	0.02	11,056 shs	10,143 shs
RXRX Recursion Pharmaceuticals	$5.64 -1.1%	$5.48	$3.79 ▼ $12.36	$2.32B	0.93	27.47 million shs	15.50 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NAMS NewAmsterdam Pharma	-2.29%	+9.63%	+19.74%	+33.32%	+48.06%
OGN Organon & Co.	+0.49%	+3.08%	-1.98%	+4.00%	-53.00%
PHAR Pharming Group	+1.16%	-6.34%	+12.67%	+20.67%	+45.71%
RXRX Recursion Pharmaceuticals	-1.05%	+4.25%	+8.05%	+23.68%	-10.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NAMS NewAmsterdam Pharma	3.5361 of 5 stars	4.4	1.0	0.0	0.0	2.6	5.0	0.0
OGN Organon & Co.	4.6966 of 5 stars	3.3	2.0	1.7	3.7	3.3	1.7	2.5
PHAR Pharming Group	2.104 of 5 stars	3.5	3.0	0.0	0.0	1.8	0.0	0.6
RXRX Recursion Pharmaceuticals	1.4777 of 5 stars	2.2	1.0	0.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.20	63.69% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	91.80% Upside
PHAR Pharming Group	3.00	Buy	$30.00	163.62% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	24.11% Upside

Current Analyst Ratings Breakdown

Latest PHAR, OGN, NAMS, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$38.00 ➝ $39.00
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NAMS NewAmsterdam Pharma	$45.56M	62.02	N/A	N/A	$6.93 per share	3.63
OGN Organon & Co.	$6.40B	0.38	$4.94 per share	1.90	$2.82 per share	3.33
PHAR Pharming Group	$297.20M	2.62	$0.07 per share	151.76	$3.50 per share	3.25
RXRX Recursion Pharmaceuticals	$58.84M	38.96	N/A	N/A	$2.26 per share	2.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NAMS NewAmsterdam Pharma	-$241.60M	-$1.62	N/A	N/A	N/A	-259.07%	-27.27%	-25.00%	N/A
OGN Organon & Co.	$864M	$2.69	3.49	2.51	0.98	11.15%	163.88%	6.99%	10/30/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.13	N/A	379.33	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	N/A	N/A	N/A	-1,004.91%	-76.09%	-54.29%	N/A

Latest PHAR, OGN, NAMS, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	-$0.15	+$0.37	-$0.15	$1.44 million	$19.15 million
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.85%	N/A	2.97%	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest PHAR, OGN, NAMS, and RXRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NAMS NewAmsterdam Pharma	N/A	21.08	21.08
OGN Organon & Co.	11.98	1.65	1.13
PHAR Pharming Group	0.38	2.79	2.07
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NAMS NewAmsterdam Pharma	89.89%
OGN Organon & Co.	77.43%
PHAR Pharming Group	0.03%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
NAMS NewAmsterdam Pharma	20.84%
OGN Organon & Co.	1.96%
PHAR Pharming Group	2.07%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
OGN Organon & Co.	4,000	259.97 million	254.87 million	Not Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable

PHAR, OGN, NAMS, and RXRX Headlines

Recent News About These Companies

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

August 14 at 2:27 AM | marketbeat.com

Recursion Pharmaceuticals: Two Clinical Readouts In H2'25

August 13 at 12:19 PM | seekingalpha.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Blair William & Co. IL

August 12 at 3:45 AM | marketbeat.com

Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

August 11, 2025 | theglobeandmail.com

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

August 10, 2025 | fool.com

Head to Head Comparison: Recursion Pharmaceuticals (NASDAQ:RXRX) & Addex Therapeutics (NASDAQ:ADXN)

August 10, 2025 | americanbankingnews.com

Leerink Partnrs Has Positive Outlook of RXRX Q3 Earnings

August 10, 2025 | americanbankingnews.com

Equities Analysts Set Expectations for RXRX Q3 Earnings

August 9, 2025 | marketbeat.com

Headlands Technologies LLC Buys 76,536 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 9, 2025 | marketbeat.com

Is Recursion Pharmaceuticals (RXRX) Nvidia's Key AI Biotech Stake a Buy Amid Innovation Surge?

August 8, 2025 | 247wallst.com

Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher

August 6, 2025 | finance.yahoo.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript

August 6, 2025 | msn.com

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

August 6, 2025 | zacks.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Expectations By $0.06 EPS

August 6, 2025 | marketbeat.com

5RXRX : Recursion Pharmaceuticals Earnings Preview

August 6, 2025 | benzinga.com

Recursion (RXRX) Q2 Revenue Jumps 33%

August 6, 2025 | theglobeandmail.com

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

August 6, 2025 | msn.com

Why Recursion Pharmaceuticals Stock Tanked on Tuesday

August 5, 2025 | fool.com

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2025 | zacks.com

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, OGN, NAMS, and RXRX Company Descriptions

NewAmsterdam Pharma NASDAQ:NAMS

$25.17 -0.59 (-2.29%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$24.83 -0.34 (-1.35%)

As of 08/14/2025 07:19 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Organon & Co. NYSE:OGN

$9.38 +0.03 (+0.27%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$9.30 -0.08 (-0.85%)

As of 04:15 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Pharming Group NASDAQ:PHAR

$11.38 +0.13 (+1.16%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$11.23 -0.15 (-1.31%)

As of 04:04 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.64 -0.06 (-1.05%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$5.76 +0.12 (+2.11%)

As of 04:41 AM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time